Welcome to our dedicated page for Genflow Biosciences news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on Genflow Biosciences stock.
Genflow Biosciences Plc develops gene therapies for age-related diseases, with company news centered on its SIRT6-based longevity platform and related therapeutic programs. Updates include progress in canine gene therapy work, intellectual property publications for SIRT6 applications, technology collaborations supporting delivery and genomic analysis, and engagement with animal health and biotechnology partners.
Genflow's announcements also cover operating and financial results, warrant exercises and equity issuance, total voting rights, and shareholder approvals for capital authorities. The company trades in London under GENF and on OTCQB under GENFF, and its public updates frequently use UK regulatory news channels for market disclosures.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) reports positive preliminary interim results from the SLAB trial testing its SIRT6 gene therapy in aged beagles. The randomised, blinded study enrolled 24 dogs aged >10 years across four groups. During the dosing period, all treated cohorts showed superior survival, functional gains and a favourable safety profile versus control. Key mechanistic endpoints—methylation clock and muscle histology—remain under analysis, with a comprehensive update expected within approximately two months.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) has called a General Meeting for 11:00 on 2 March 2026 to seek shareholder authority to issue up to 188,947,368 new ordinary shares (~38% of current issued share capital) to enable a potential equity raise.
The raise would be by private placement, may include warrants, and proceeds are intended for IND-enabling work on MASH, an aged-beagle trial payment, glaucoma PoC studies, business development, and patent work.
Genflow Biosciences (OTC:GENFF) major-holdings notice: Jonathan Mark Swann crossed a regulatory threshold, increasing his direct voting stake to 12.13% of voting rights (59,861,278 votes) on 23-Jan-2026. The issuer notified the market on 25-Jan-2026 and the completion date is listed as 24-Jan-2026.
The filing shows a prior position of 11.32% (55,861,278 votes), no voting rights via financial instruments, and no additional information disclosed.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) received administrative approval for approximately €4 million in non-dilutive funding from the Wallonia Region to support GF-1002 development for MASH.
First instalment expected no later than May 2026; support covers a three-year programme and makes 2026 priorities capital-efficient, with multiple programme readouts planned.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) appointed Gad Berdugo as Independent Non-Executive Chairman effective immediately, while Tamara Joseph remains on the board to preserve continuity and governance. Mr. Berdugo brings over 30 years of leadership across biotech corporate development, U.S. capital markets and RNA-LNP therapeutics, and currently leads Explorium Capital LLC. The company said his expertise will support advancement of gene-therapy programs, evaluation of delivery technologies, and expanded U.S. engagement. Management highlighted key data readouts expected in 2026. The announcement notes Mr. Berdugo does not own any Genflow shares.
Genflow (OTCQB:GENFF) reported completion of the dosing phase in its blinded canine trial of a SIRT6-based gene therapy on December 16, 2025. All enrolled dogs received full dosing and no adverse events were reported during administration.
Genflow expects a first efficacy read in mid-to-late January 2026 (blood analyses and muscle biopsies) and a second efficacy assessment at the six-month (180-day) timepoint with results expected in June–July 2026. The company plans to resume licensing discussions after efficacy analysis.
Genflow (OTCQB:GENFF) will attend the 44th Annual J.P. Morgan Healthcare Conference on January 12–15, 2026 at the Westin St. Francis in San Francisco.
Participation aims to facilitate meetings with potential partners, institutional investors, and pharmaceutical companies as the company advances its gene‑therapy pipeline targeting the SIRT6 longevity pathway. The appearance is an investor‑relations and business‑development opportunity at a major industry event.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced its total issued share capital and voting rights as at 31 October 2025. The company reported 493,547,942 Ordinary Shares outstanding, with none held in treasury, making the total number of voting rights 493,547,942.
Shareholders may use this figure as the denominator to determine whether they must notify a change in their holding under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Genflow Biosciences (OTC:GENFF) disclosure shows Jonathan Mark Swann increased his holding to 11.32% of voting rights in Genflow Biosciences on 23-Oct-2025, up from 8.40% in the prior notification.
The resulting position equals 55,861,278 voting rights. No financial instruments were reported; the notification lists completion in London on 23-Oct-2025 and states no additional information.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced publication of its second European patent application (Application No. 23821586.7; Publication No. EP4630038) titled “SIRT6 Variant for NASH” in the European Patent Bulletin on October 22, 2025.
The publication follows entry into the European phase under the PCT and provides provisional protection under Article 67(3) EPC, enabling retroactive damages for infringing acts after publication once the patent is granted and national validations are completed. The filing complements the company’s earlier EP4338267 SIRT6 variant application and is presented as part of Genflow’s strategy to expand IP coverage across metabolic and age‑related disorders and support upcoming clinical programs.